McKesson Total Cost of Revenue decreased by 10.0% to $92.25B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 87.9%, from $49.10B to $92.25B. Over 4 years (FY 2022 to FY 2026), Total Cost of Revenue shows an upward trend with a 12.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $59.64B | $63.22B | $65.19B | $52.33B | $64.13B | $67.06B | $67.32B | $41.00B | $71.46B | $74.15B | $77.75B | $37.58B | $76.13B | $90.40B | $92.01B | $49.10B | $94.55B | $99.61B | $102.47B | $92.25B |
| QoQ Change | — | +6.0% | +3.1% | -19.7% | +22.6% | +4.6% | +0.4% | -39.1% | +74.3% | +3.8% | +4.9% | -51.7% | +102.6% | +18.7% | +1.8% | -46.6% | +92.6% | +5.4% | +2.9% | -10.0% |
| YoY Change | — | — | — | — | +7.5% | +6.1% | +3.3% | -21.6% | +11.4% | +10.6% | +15.5% | -8.3% | +6.5% | +21.9% | +18.3% | +30.7% | +24.2% | +10.2% | +11.4% | +87.9% |